Live Breaking News & Updates on Initiate Pivotal Trial

On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022BOSTON (BUSINESS WIRE) Aura Biosciences Inc. (NASDAQ: AURA), a clinical. ....

United States , Matthew Deyoung , Los Pinos , Aura Biosciences Inc , American Society Of Clinical Oncology , Exchange Commission , International Society Of Ocular Oncology , Association Of Research , Division Of Oncology , First Patient , Evaluating Belzupacap Sarotalocan , Non Muscle Invasive Bladder Cancer , Initiate Pivotal Trial , Early Stage Choroidal Melanoma , Aura Biosciences , Elisabet De Los Pinos , Chief Executive Officer , Investigational New Drug , International Society , Ocular Oncology , Annual Meeting , Retrospective Match Case Control , Fast Track , Clinical Oncology , Private Securities Litigation Reform Act , Annual Report ,